Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Weighted Average) (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $27.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.43% year-over-year to $27.4 million, compared with a TTM value of $27.4 million through Dec 2025, up 1.43%, and an annual FY2025 reading of $27.4 million, up 1.43% over the prior year.
- Shares Outstanding (Weighted Average) was $27.4 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $27.2 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $27.4 million in Q4 2025 and bottomed at $26376.0 in Q1 2022.
- Average Shares Outstanding (Weighted Average) over 5 years is $22.7 million, with a median of $26.6 million recorded in 2023.
- The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.9% in 2022, then soared 100578.65% in 2023.
- Year by year, Shares Outstanding (Weighted Average) stood at $26.3 million in 2021, then grew by 0.49% to $26.4 million in 2022, then increased by 0.69% to $26.6 million in 2023, then rose by 1.4% to $27.0 million in 2024, then rose by 1.43% to $27.4 million in 2025.
- Business Quant data shows Shares Outstanding (Weighted Average) for ARCT at $27.4 million in Q4 2025, $27.2 million in Q3 2025, and $27.1 million in Q2 2025.